Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 310 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... August 24, 2020 New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... May 20, 2021 Fears breast cancer progress could stall due to COVID-19 backlog June 15, 2021 Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... January 8, 2024 Load more HOT NEWS New Blood Test Can Screen For Over 50 Cancers Cancer Drug Lynparza Found to Lower Risk of Death and Recurrence... Mom Who Lost Child Donates Breast Milk To Mom With Cancer Dog Finds Woman’s Lost Wedding Ring At The Beach
